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Purpose: To evaluate the feasibility and efficacy of endovascular therapy combined with
immunosuppression for the treatment of arterial occlusive disease in patients with Tak-
ayasu’s arteritis (TA).
Methods: From January 1998 to June 2003, 25 patients (22 women; age 37.8615.5 years)
with TA were treated with angioplasty for symptomatic lesions or with a hemodynamically
significant aortic narrowing. The patients with active disease, defined as an increase in
inflammatory markers (e.g., erythrocyte sedimentation rate [ESR]), were treated with im-
munosuppressive agents before intervention. Angioplasty was performed after the ESR
had been normalized.
Results: In the 25 patients, 58 vascular territories (7 aortic, 9 carotid, 3 vertebral, 11 sub-
clavian, 2 superior mesenteric, 18 renal, 4 iliac, and 4 coronary arteries) were treated with
angioplasty only (19 lesions) or with stents (39 lesions). The mean ESR when the vascular
lesions were initially diagnosed was 35.6626.2 mm/h, which fell to 18.567.8 mm/h after
immunosuppressive therapy. The endovascular procedure was performed successfully in
52 (90%) of 58 lesions. During the mean 23.7618.4-month follow-up, 9 (17%) treated seg-
ments restenosed; 4 were treated with repeat angioplasty. The overall cumulative primary
clinical success rate was 82%; secondary clinical success was 90%.
Conclusions: Endovascular therapy for stenotic lesions in patients with TA is safe and
effective when disease activity is strictly controlled with immunosuppressive treatment.
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Endovascular management has become an
established treatment for atherosclerotic oc-
clusive diseases, but relatively few studies
have dealt with interventional treatment of
vasculitic disorders. Takayasu’s arteritis (TA)
is a chronic inflammatory disease of unknown
etiology that involves the aorta, its major
branches, and the pulmonary arteries. The
disease leads to stenosis/occlusion or aneu-
rysm formation or both.1,2 The management
of TA is challenging. Steroids and immuno-
suppressive agents have been used with var-
iable success.3,4 Revascularization procedures
are usually performed for significant stenotic
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lesions.5 Initial reports revealed excellent re-
sults of percutaneous transluminal angioplas-
ty (PTA) in patients with TA.6–8 However, res-
tenosis remains a major concern with PTA.9,10
Stent-supported angioplasty achieves better
luminal diameter and lowers the rate of res-
tenosis.11,12 At present, most publications on
stent-supported PTA in Takayasu’s arteritis
are isolated case reports or small series.13–15
We report our experience with 25 TA patients
who underwent endovascular therapy com-
bined with immunosuppressive treatment for
stenotic lesions in various vascular territories.
METHODS
Patient Sample and Treatment
Indications
Twenty-five patients (22 women; mean age
37.8615.5 years, range 9–68) with angio-
graphically proven TA underwent endovas-
cular treatment of arterial occlusive disease
between January 1998 and June 2003. All pa-
tients fulfilled the American College of Rheu-
matology classification criteria for TA.16 An-
giographic findings based on the
International Collaborative Study Group17
were classified as type I in 4 patients (involv-
ing the coronary artery in 2), type IIb in 1, type
III in 3, type IV in 5 (1 with a coronary lesion),
and type V in 12 (3 had coronary lesions).
Indications for angioplasty included symp-
tomatic stenosis .70% of the reference di-
ameter in arteries or a hemodynamically sig-
nificant aortic narrowing (peak systolic
pressure gradient .50 mmHg across the ste-
notic lesion). Stenting was performed for os-
tial lesions, chronically occluded vessels,
long-segment lesions, inadequate dilation, or
dissection following angioplasty. An informed
written consent was obtained from all pa-
tients prior to the procedure.
Patients with active disease judged by sys-
temic features, e.g., fever, musculoskeletal
pains, or elevated erythrocyte sedimentation
rate (ESR), received immunosuppressive ther-
apy before the endovascular treatment. The
ESR was measured by the Westergren meth-
od (Espette, Korea; reference range ,15 mm/
h in men and ,20 mm/h in women). Prednis-
olone (1 mg/kg/d) was used as the first-line
immunosuppressive drug; in patients unre-
sponsive to steroid, methotrexate (7.5 mg/wk)
was added. The doses of immunosuppressive
agents were adjusted according to the ESR
and clinical status of the patients. Angioplasty
was performed after the ESR had been nor-
malized in these patients.
Angioplasty Techniques
All patients undergoing angioplasty were
given aspirin (100 mg/d) and ticlopidine (250
mg bid for stenting) prior to the procedure.
Using standard catheterization techniques, ar-
terial access was obtained (21 femoral, 1 bra-
chial, and 3 femoral-brachial). Intravenous
heparin was administered during the proce-
dure to maintain an activated coagulation
time between 250 and 300 seconds. In gen-
eral, balloons were inflated with increasing
pressure until the waist on the balloon dis-
appeared; tandem dilations were used for
long-segment lesions. Stents were deployed
using the rolling membrane delivery device or
over-the-balloon technique; the stents were
postdilated with high-pressure inflations.
For aortic angioplasty, the lesion was
crossed with a 0.035-inch hydrophilic guide-
wire (Terumo, Tokyo, Japan), which was ex-
changed for a similarly sized extra-stiff gui-
dewire (Cook, Bloomington, IN, USA).
Angioplasty of the stenotic segment was
done using 14 to 18-mm-diameter Medi-tech
XXL balloons (Boston Scientific, Natick, MA,
USA) or a 7 to 12-mm UDT balloon (Boston
Scientific). In the aorta, 10380-mm SMART
stents (Cordis, a Johnson & Johnson com-
pany, Warren, NJ, USA) or 22 to 25-mm by 40
to 60-mm nitinol stents (Taewoong, Seoul,
Korea) were implanted. High pressure (14 to
18 atmospheres) was required to optimally di-
late the lesions.
For aortic arch vessels, a Shuttle sheath
(Cook) was placed near the lesion, which was
crossed with a 0.018-inch extra-support Road-
runner guidewire (Cook). The lesion was di-
lated with 4 to 6-mm by 20 to 40-mm balloons
(Symmetry or UDT, Boston Scientific; Power-
flex, Cordis); a variety of stents ranging from
6 to 8 in diameter by 13 to 43 mm long were
used: Palmaz (Cordis), SMART (Cordis), Corin-
thian (Cordis), Easy Wallstent (Boston Scien-
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TABLE
Comparison of Diameter Stenosis Before and After Angioplasty With or Without
Stenting in 25 Patients With Takayasu’s Arteritis
Arteries
Diameter Stenosis, %
Pre Post p
Aorta (n57) 69.6613.0 34.6614.8 0.002
(69.9636.6*) (17.0612.9*) (0.004)
Carotid (n59) 82.7611.4 15.3618.2 0.002
Vertebral (n53) 73.365.8 20.0626.5 0.094
Subclavian (n511) 84.1612.6 18.2619.8 ,0.001
Mesenteric (n52) 75.067.1 25.0635.4 0.242
Renal (n518) 85.868.3 17.2619.3 ,0.001
Common iliac (n54) 75.0610.0 17.5612.6 0.014
Coronary (n54) 79.367.1 7.063.7 ,0.001
l l
* Peak systolic pressure gradient, mmHg.
tific), or Jostent (Jomed GmbH, Rangendin-
gen, Germany). The maximum dilation
pressures were 4 to 15 atmospheres; stents
were postdilated at 6 to 15 atmospheres.
Small vessels or severe lesions ,4 mm long
were predilated with coronary balloons
(Adante; Boston Scientific); later, larger pe-
ripheral angioplasty balloons were used. Cor-
onary stents (NIR; Boston Scientific) were
used in the vertebral artery. In the patients
with renal artery stenosis, a guiding catheter
was placed into the renal artery ostium, and
a 0.018-inch guidewire was introduced into
the lesion. Peripheral balloon catheters
ranged from 4 to 7 mm by 10 to 40 mm, and
the stents measured 6 to 9 mm by 12 to 20
mm. Maximum inflation pressures were 10 to
18 atmospheres.
In patients receiving stents, ticlopidine was
administered for 1 month. Aspirin was contin-
ued indefinitely after the procedure in all pa-
tients. After endovascular treatment, the dos-
age of immunosuppressive drugs in patients
with active disease was adjusted to maintain
the serum ESR level within the normal range.
Definitions and Follow-up
An intervention was considered technically
successful if the residual stenosis was ,30%
or the pressure gradient across the lesion was
,50% of the value before treatment. Surveil-
lance was conducted every 3 months in our
outpatient clinic. Long-term success of the en-
dovascular procedure was documented by
angiography, computed tomography (CT),
magnetic resonance angiography (MRA), or
color-flow duplex ultrasound (CDU). Symp-
tom recurrence and hemodynamic changes
were primary criteria for clinical assessment
of restenosis. Detailed criteria for restenosis
relative to each vascular territory were: hy-
pertension, lower limb claudication, or con-
gestive heart failure for aortic lesions; synco-
pe, dizziness, transient ischemic attack, or
stroke for the carotid and vertebral lesions;
arm claudication, decreased pulsation, or sys-
tolic pressure differential between the arms
for subclavian lesion; nausea, vomiting, or
abdominal pain for the mesenteric lesions;
hypertension or renal insufficiency for the re-
nal lesions; and chest pain for the coronary
lesions.
RESULTS
Mean duration of immunosuppressive thera-
py prior to endovascular treatment in the 16
patients with active disease was 17.6621.5
days (range 3–66). The mean ESR at diagnosis
was 35.6626.2 mm/h (range 2–106), which fell
to 18.567.8 mm/h (range 2–32) after the im-
munosuppressive therapy. In all 25 patients,
54 stenoses and 4 occlusions were treated us-
ing endovascular techniques in the aorta
(n57), the coronary arteries (n54), and vari-
ous peripheral vessels (n547, Table). Angio-
plasty alone was performed in 19 lesions (Fig.
1); 39 arteries received stents (Fig. 2). Final an-
giography performed immediately after inter-
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Figure 1l (A) The aortogram of a 30-year-old man with severe hypertension and claudication
shows a severe stenosis of the abdominal aorta. The peak pressure gradient across the lesion
was 41 mmHg. (B) Aortogram after balloon angioplasty with an 18320-mm Medi-tech XXL
balloon revealed marked improvement of the aortic lumen. There was no residual pressure
gradient. (C) At the follow-up 8 months later, the abdominal aortic lumen is maintained with-
out restenosis.
vention revealed a successful initial result in
52 (90%) of 58 lesions. Three of the 4 total
occlusions were successfully recanalized, and
53 (98%) of 54 stenoses were reduced. Angio-
plasty could not be performed in 1 total oc-
clusion and 1 web-like stenosis. The proce-
dure was also suboptimal (residual diameter
stenosis .30%) in 4 stenotic lesions. There
were no major complications, such as acute
thrombosis, severe dissection, stroke, myo-
cardial infarction, emergency surgery, or
death.
During a mean 16.8612.9-month follow-up
(range 6–43), 35 (67%) of the 52 successfully
treated lesions were followed using angiog-
raphy (n527), CT (n53), MRA (n53), or CDU
(n52). Nine patients with 17 lesions declined
further imaging. Restenoses occurred in 9
vascular lesions (9/35, 26%). Clinical symp-
toms recurred in 1 patient in whom restenosis
was confirmed angiographically. Six (46%) of
the restenoses were in the 13 lesions that
were initially successfully dilated; the other 3
recurrences were in-stent restenoses (8% of
the 22 stented lesions objectively evaluated).
Four of 9 restenoses were treated successful-
ly with repeat angioplasty. The cumulative
primary clinical success rate for the 35 suc-
cessfully treated lesions that were objectively
evaluated at a mean 17-month follow-up was
80%68% (6standard error). Repeat dilation in
4 lesions led to a cumulative secondary suc-
cess rate of 86%67%.
DISCUSSION
The treatment modalities of TA usually in-
clude medical therapy with steroids or the
combination of immunosuppressive agents
and revascularization procedures.3,4,6 In the
chronic stage, the principle of treatment is re-
vascularization of the affected organ either by
surgery or angioplasty.6,9,15,18 Surgical bypass
of the stenosed segment is oftentimes com-
plicated by graft reocclusion, anastomotic site
aneurysm, and morbidity.5,19 In general, the
progressive inflammatory nature of the dis-
ease has precluded widespread use of recon-
structive surgery. Angioplasty offers a less in-
vasive, cost-effective, and safe method for
relief of stenotic lesions in patients with TA.12
The initial technical success rate of angio-
plasty in TA is usually high. Deyu et al.20
achieved an 89.2% initial success rate and
symptomatic improvement in renal stenoses
due to TA. Sharma et al.21 reported a technical
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Figure 2l (A) Left subclavian artery stenosis in a 66-year-old woman suffering from left arm
claudication. (B) Angiogram after a self-expanding Easy Wallstent (8340-mm) was implanted;
there is no residual stenosis. (C) The follow-up angiogram 43 months later revealed a patent
stent with minimal neointimal hyperplasia. There was no pressure gradient across the stent,
and good distal flow was observed.
success rate of ;95% combined with a clinical
success rate of 89% after renal angioplasty. In
obstructions of the subclavian artery, initial
success rates of 86.5%22 and 81%8 have been
observed after PTA. In a study concerning
stent-supported PTA in aortic stenosis due to
TA, intervention was initially successful in all
treated patients.13 The 90% technical success
rate achieved in our patients is comparable
with previous studies involving this patholo-
gy.
Our results demonstrate that endovascular
treatment of occlusive arterial lesions due to
TA is safe and feasible, with high technical
success and no procedure-related morbidity.
However, atherosclerotic lesions seem to re-
spond better to dilation, as proven in a study
by Tyagi et al.22 They documented a 15.5% re-
sidual stenosis after subclavian artery PTA in
Takayasu’s arteritis compared with only 8.3%
residual stenosis in atherosclerotic lesions. In
our study, residual stenosis after PTA in sub-
clavian arteries was 18.2%.
Initial technical results in vasculitic lesions
are promising, but restenosis still remains a
major concern. Both et al.23 reported a cu-
mulative primary patency rate of 67.6% in dif-
ferent forms of vasculitis. In previous studies
concerning PTA in obstructive vascular le-
sions due to TA, restenosis was seen in 16%
to 25% of all lesions treated successfully at
initial angioplasty.20–22 In meta analyses of
PTA in atherosclerotic lesions, restenosis
rates seemed relatively lower than in TA:
17%24 after renal artery stenting and 3% after
stenting in subclavian arteries.25
Thus, our approach included strict control
of active disease with the administration of
immunosuppressive agents before and after
the endovascular treatment. The intensity and
duration of the immunosuppressive regimen
were determined according to each patient’s
clinical condition and disease activity. Pred-
nisolone was given to all patients with ele-
vated ESR before endovascular treatment;
methotrexate was added if a patient was un-
responsive to steroids. Because no single cy-
totoxic drug appears to be better than any
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other in terms of efficacy, side-effect profiles
have been an important driving force in de-
termining treatment. Steroid and methotrex-
ate have been reported to be useful and well-
tolerated,26 and this protocol was successful
in lowering the ESR before intervention in our
study. Moreover, the $80% patency rates in
the subset of patients undergoing periodic
imaging up to a mean of 17 months suggest
that endovascular treatment combined with
immunosuppressive therapy is a promising
therapeutic regimen in TA.
In summary, endovascular treatment is a
safe and effective treatment of occlusive ar-
terial disease in patients with TA. Before and
after endovascular treatment, disease activity
should be strictly controlled with immuno-
suppressive therapy. However, further long-
term study with a larger population is needed
to confirm the long-term efficacy of this mo-
dality as a treatment for occlusive arterial dis-
ease due to Takayasu’s arteritis.
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